Ignite Creation Date:
2025-12-24 @ 4:22 PM
Ignite Modification Date:
2026-03-08 @ 3:30 AM
Study NCT ID:
NCT03340766
Status:
COMPLETED
Last Update Posted:
2024-10-17
First Post:
2017-10-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Sponsor:
Amgen
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
20150290
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |